Evommune, Inc. (EVMN) Financial Statements

Income statement

Metric	TTM	2025	2024	2023
Revenue
Total Revenue	10.0M	13.0M	7.0M	5.0M
Cost of Revenue	349.0K	—	1.3M	1.0M
Gross Profit	9.7M	13.0M	5.7M	4.0M
Operating Expenses
R&D Expense	83.8M	74.0M	64.2M	32.0M
SG&A Expense	27.8M	20.0M	11.5M	9.9M
General & Admin Expense	19.3M	20.0M	—	—
Selling & Marketing Expense	2.1M	—	—	—
Other Expenses	—	—	—	—
Total Operating Expenses	111.5M	94.1M	75.7M	41.9M
Cost and Expenses	111.9M	94.1M	77.0M	42.9M
Operating Income (EBIT)	(101.9M)	(81.1M)	(70.0M)	(37.9M)
Non-Operating
Interest Income	7.2M	3.3M	3.2M	3.9M
Interest Expense	—	—	34.0K	58.0K
Net Interest Income	7.2M	3.3M	3.2M	3.8M
Other Non-Op Income/Expense	7.2M	12.2M	3.2M	3.8M
Non-Operating Income (excl Interest)	(4.6M)	(12.2M)	(3.2M)	(3.9M)
EBT (Pre-Tax Income)	(94.7M)	(68.9M)	(66.8M)	(34.1M)
Income Tax Expense	—	—	—	—
Bottom Line
Net Income	(94.7M)	(68.9M)	(66.8M)	(34.1M)
Earnings from Cont. Ops	(94.7M)	(68.9M)	(66.8M)	(34.1M)
Earnings from Discont. Ops	—	—	—	—
Bottom Line Net Income	(94.7M)	(68.9M)	(68.3M)	(34.1M)
Per Share
Basic EPS	($2.83)	($2.18)	($2.27)	($1.13)
Diluted EPS	($2.83)	($2.18)	($2.27)	($1.13)
Revenue Per Share	$0.28	$0.41	$0.23	$0.17
Shares
Basic Shares Outstanding	36.1M	31.5M	30.1M	30.1M
Diluted Shares Outstanding	36.1M	31.5M	30.1M	30.1M
Profitability Metrics
EBITDA	(95.8M)	(67.5M)	(65.5M)	(33.0M)
D&A	1.5M	1.4M	1.3M	1.0M
EBIT	(97.3M)	(68.9M)	(66.8M)	(34.0M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026